Bolt Biotherapeutics is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjugate (ISAC) approach uses immunostimulants to engage and activate myeloid cells that directly kill tumor cells. This leads to the conversion of immunologically “cold” tumors to “hot” tumors.
Our lead candidate, BDC-1001, is a Boltbody ISAC comprised of a HER2-targeting biosimilar of trastuzumab conjugated to one of our proprietary TLR7/8 agonists for the treatment of patients with HER2-expressing solid tumors. We believe that our preliminary Phase 1/2 data from our ongoing clinical trial provide us with clinical proof of concept for our HER2 Boltbody ISAC approach.
Bolt is also advancing additional Boltbody ISAC product candidates targeting CEA and PD-L1.
June 4, 2021
Bolt Biotherapeutics Presents Preliminary Results from Phase 1/2 Trial of Lead HER2-targeting Boltbody™ ISAC BDC-1001 at ASCO 2021Read More
June 2, 2021
Genmab and Bolt Biotherapeutics Announce Oncology Research and Development CollaborationRead More
May 13, 2021
Bolt Biotherapeutics Reports First Quarter 2021 Financial Results and Provides Business HighlightsRead More
June 4, 2021
2021 American Society of Clinical Oncology (ASCO) Annual Meeting Read More
April 15, 2021 at 10:15 AM EDT
20th Annual Needham Virtual Healthcare Conference Read More
April 10, 2021
American Association for Cancer Research (AACR) Annual Meeting 2021 Read More